Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$8.27B |
$162.34
-1.06%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$8.23B |
$67.53
-3.56%
|
|
PRAX
Praxis Precision Medicines, Inc.
Solidus platform develops antisense oligonucleotide (ASO) therapeutics (e.g., elsunersen).
|
$8.13B |
$313.93
-3.44%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$7.87B |
$58.99
-1.90%
|
|
KRYS
Krystal Biotech, Inc.
Krystal Biotech's core HSV-1 gene therapy platform and lead product VYJUVEK directly represent a gene therapy business.
|
$7.68B |
$256.63
-3.16%
|
|
BIO
Bio-Rad Laboratories, Inc.
Bio-Rad's Saber Bio antibody discovery platform represents a dedicated platform for high-throughput antibody and T cell receptor discovery.
|
$7.68B |
$283.83
-0.30%
|
|
CYTK
Cytokinetics, Incorporated
Cytokinetics' core programs target cardiovascular diseases (aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil and ulacamten), making 'Cardiovascular Drugs' the primary investable theme.
|
$7.61B |
$61.53
-1.19%
|
|
GRFS
Grifols, S.A.
Grifols operates as a large, global pharmaceutical company with a core focus on plasma-derived therapies.
|
$7.51B |
$8.75
+1.04%
|
|
NUVL
Nuvalent, Inc.
Nuvalent is a oncology-focused biotechnology company developing targeted cancer therapies (ROS1/ALK inhibitors), fitting Biotech - Oncology.
|
$7.46B |
$100.07
-2.53%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$7.41B |
$114.70
-1.77%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
MRUS
Merus N.V.
Company develops multispecific antibody therapeutics for oncology, including lead candidates like petosemtamab and BIZENGRI.
|
$6.81B |
$90.00
|
|
GKOS
Glaukos Corporation
Glaukos markets ophthalmic drugs such as iDose TR and corneal health therapies (Photrexa, Epioxa), which are administered to treat eye conditions.
|
$6.63B |
$112.30
-2.66%
|
|
ACLX
Arcellx, Inc.
Company's lead products are CAR-T cell therapies within oncology; direct product category is cell therapy.
|
$6.61B |
$114.30
|
|
BLCO
Bausch + Lomb Corporation
Ophthalmic Drugs – direct development, licensing, and commercialization of eye-disease medications (e.g., MIEBO, XIIDRA).
|
$6.39B |
$17.64
-2.27%
|
|
KYMR
Kymera Therapeutics, Inc.
Kymera's core offering is oral small molecule therapeutics designed to degrade disease-causing proteins (STAT6, IRAK4, IRF5) in immunology indications.
|
$6.20B |
$83.12
-3.47%
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Rhythm's core business is developing and commercializing therapies for ultra-rare diseases (e.g., setmelanotide for MC4R pathway deficiencies, BBS), a hallmark of rare-disease biotech.
|
$6.07B |
$90.76
-0.26%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$5.93B |
$91.45
-3.56%
|
|
CRSP
CRISPR Therapeutics AG
CRISPR-based ex vivo gene-editing therapy CASGEVY is a gene therapy product.
|
$5.72B |
$57.58
-4.03%
|
|
BLTE
Belite Bio, Inc
Lead product Tinlarebant is an ophthalmic drug targeting retinal diseases (STGD1/GA).
|
$5.66B |
$174.84
-1.66%
|
|
CDTX
Cidara Therapeutics, Inc.
CD388 is an antiviral small-molecule therapeutic targeting neuraminidase for universal influenza prevention and treatment.
|
$5.61B |
$221.39
+0.00%
|
|
STVN
Stevanato Group S.p.A.
Provides Drug Delivery Platforms as integrated containment and delivery solutions for biologics.
|
$5.30B |
$15.95
-8.86%
|
|
COGT
Cogent Biosciences, Inc.
Cogent's lead asset bezuclastinib and the described pipeline assets are primarily oral small-molecule tyrosine kinase inhibitors, i.e., Oral Small Molecule Therapeutics.
|
$5.27B |
$37.76
+1.99%
|
|
UUUU
Energy Fuels Inc.
Radium/radioisotope recovery plans for targeted alpha therapy isotopes (radiopharmaceuticals).
|
$5.18B |
$20.24
-7.20%
|
|
PTCT
PTC Therapeutics, Inc.
Sephience PKU and other PTC therapies are oral small-molecule drugs, a major product category for the company.
|
$5.16B |
$62.81
-2.30%
|
|
LNTH
Lantheus Holdings, Inc.
Directly produces radiopharmaceutical imaging agents and related therapies (e.g., PYLARIFY, DEFINITY) and maintains an expanding pipeline in this modality.
|
$5.16B |
$75.56
-2.93%
|
|
CGON
CG Oncology, Inc. Common stock
CG Oncology is a biotech company focused on oncology therapies, with cretostimogene grenadenorepvec representing an oncology product in late-stage development.
|
$4.97B |
$60.84
-1.18%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.94B |
$70.90
-1.95%
|
|
IEP
Icahn Enterprises L.P.
Pharma segment includes global drug development and commercialization activities (eg. Qsiva) typical of Large Cap Pharma companies.
|
$4.92B |
$8.29
+1.28%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.84B |
$47.25
-0.38%
|
|
ALKS
Alkermes plc
Direct product category encompassing Alkermes' oral small-molecule therapeutics, including LYBALVI.
|
$4.83B |
$28.39
-3.02%
|
|
OLED
Universal Display Corporation
Contract research services via Adesis subsidiary.
|
$4.83B |
$100.49
-1.01%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$4.78B |
$91.95
-1.17%
|
|
CELC
Celcuity Inc.
Core asset gedatolisib targets oncology indications, placing Celcuity squarely in Biotech - Oncology.
|
$4.76B |
$114.09
+1.70%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.75B |
$26.88
-0.76%
|
Showing page 4 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
